Suven Life Sciences Ltd
NSE: SUVEN BSE: 530239
₹210.18
(7.19%)
Thu, 23 Apr 2026, 05:31 pm
Market Cap51.66B
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KSuven Life Sciences Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends per share have been stable in the past 10 years.
- Suven Life Sciences's pays a higher dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Suven Life Sciences's dividend is above the markets top 25% of dividend payers in India (3.08%).
- The company is paying a dividend however it is incurring a loss.
future
- Suven Life Sciences is expected to become profitable in 1 year.
health
- Suven Life Sciences is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Suven Life Sciences has been profitable on average in the past, therefore cash runway is not a concern.
- Suven Life Sciences has been profitable on average in the past, therefore cash runway is not a concern.
- Debt is covered by short term assets, assets are 60.8x debt.
- Suven Life Sciences's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (19.4% vs 0.8% today).
- Suven Life Sciences's level of debt (0.8%) compared to net worth is satisfactory (less than 40%).
- Operating cash flow is negative therefore debt is not well covered.
- High level of physical assets or inventory.
management
- The tenure for the Suven Life Sciences board of directors is about average.
- The average tenure for the Suven Life Sciences management team is over 5 years, this suggests they are a seasoned and experienced team.
- Venkat's remuneration is higher than average for companies of similar size in India.
- Venkat's compensation has increased whilst company is loss making.
misc
- Suven Life Sciences is not covered by any analysts.
- Suven Life Sciences has significant price volatility in the past 3 months.
past
- Unable to compare Suven Life Sciences's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Suven Life Sciences does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- It is difficult to establish if Suven Life Sciences has efficiently used its assets last year compared to the IN Pharmaceuticals industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Suven Life Sciences improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
- It is difficult to establish if Suven Life Sciences has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- Unable to compare Suven Life Sciences's 1-year growth to the IN Pharmaceuticals industry average as it is not currently profitable.
value
- Suven Life Sciences's share price is below the future cash flow value, but not at a moderate discount (< 20%).
- Suven Life Sciences's share price is below the future cash flow value, but not at a substantial discount (< 40%).
- Suven Life Sciences is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- Suven Life Sciences is loss making, we can't compare its value to the IN Pharmaceuticals industry average.
- Suven Life Sciences is loss making, we can't compare the value of its earnings to the India market.
- 530239 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 530239 underperformed the Market in India which returned -14.5% over the past year.
- BSE:530239 is down -15.5% underperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:530239 is down -15.5% underperforming the market in India which returned 8% over the past month.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800